AU2014201660B2 - Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas - Google Patents
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas Download PDFInfo
- Publication number
- AU2014201660B2 AU2014201660B2 AU2014201660A AU2014201660A AU2014201660B2 AU 2014201660 B2 AU2014201660 B2 AU 2014201660B2 AU 2014201660 A AU2014201660 A AU 2014201660A AU 2014201660 A AU2014201660 A AU 2014201660A AU 2014201660 B2 AU2014201660 B2 AU 2014201660B2
- Authority
- AU
- Australia
- Prior art keywords
- medicament
- hemangiomas
- beta
- propranolol
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 201000011066 hemangioma Diseases 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 239000002876 beta blocker Substances 0.000 title abstract description 60
- 229940097320 beta blocking agent Drugs 0.000 title abstract description 56
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract description 94
- 229960003712 propranolol Drugs 0.000 claims abstract description 45
- 208000001969 capillary hemangioma Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 13
- 239000006188 syrup Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000012669 liquid formulation Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 229940042126 oral powder Drugs 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- AQHHHDLHHXJYJD-CQSZACIVSA-N (R)-(+)-propranolol Chemical compound C1=CC=C2C(OC[C@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-CQSZACIVSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 229940102223 injectable solution Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229940098462 oral drops Drugs 0.000 claims description 4
- AQHHHDLHHXJYJD-AWEZNQCLSA-N (2s)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2C(OC[C@@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-AWEZNQCLSA-N 0.000 claims description 3
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 claims description 3
- 208000009660 capillary infantile hemangioma Diseases 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 229960004604 propranolol hydrochloride Drugs 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 abstract description 5
- 108010050904 Interferons Proteins 0.000 abstract description 4
- 102000014150 Interferons Human genes 0.000 abstract description 4
- 229960001334 corticosteroids Drugs 0.000 abstract description 4
- 229940079322 interferon Drugs 0.000 abstract description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract description 4
- 229960004528 vincristine Drugs 0.000 abstract description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 9
- 229960005205 prednisolone Drugs 0.000 description 8
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 210000001043 capillary endothelial cell Anatomy 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 6
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 5
- 239000002870 angiogenesis inducing agent Substances 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 4
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960002122 acebutolol Drugs 0.000 description 4
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 4
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 4
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 4
- 229960004324 betaxolol Drugs 0.000 description 4
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 4
- 229960001222 carteolol Drugs 0.000 description 4
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 4
- 229960004195 carvedilol Drugs 0.000 description 4
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960001632 labetalol Drugs 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229960004570 oxprenolol Drugs 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229960002035 penbutolol Drugs 0.000 description 4
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 4
- 229960002508 pindolol Drugs 0.000 description 4
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 3
- 230000001800 adrenalinergic effect Effects 0.000 description 3
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 208000004731 long QT syndrome Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000035752 proliferative phase Effects 0.000 description 3
- 229960000203 propafenone Drugs 0.000 description 3
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 2
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 2
- 206010049021 Axillary mass Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 2
- 241000083547 Columella Species 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000002125 Hemangioendothelioma Diseases 0.000 description 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 229960002213 alprenolol Drugs 0.000 description 2
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- -1 atenoloi Chemical compound 0.000 description 2
- 229960002781 bisoprolol Drugs 0.000 description 2
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229950005341 bucindolol Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960002320 celiprolol Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 2
- 229960003745 esmolol Drugs 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 230000009249 intrinsic sympathomimetic activity Effects 0.000 description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 2
- 229960000831 levobunolol Drugs 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229950008578 medroxalol Drugs 0.000 description 2
- MPQWSYJGFLADEW-UHFFFAOYSA-N medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 description 2
- 229960003134 mepindolol Drugs 0.000 description 2
- 229960002704 metipranolol Drugs 0.000 description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 229960000619 nebivolol Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BNRANURXPKRRKP-UHFFFAOYSA-N 1-[tert-butyl-[(4-methylphenyl)methyl]amino]-3-(1H-indol-4-yloxy)propan-2-ol Chemical compound Cc1ccc(CN(CC(O)COc2cccc3[nH]ccc23)C(C)(C)C)cc1 BNRANURXPKRRKP-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100022183 E3 ubiquitin-protein ligase MIB1 Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000973503 Homo sapiens E3 ubiquitin-protein ligase MIB1 Proteins 0.000 description 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 101710178181 Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 206010028747 Nasal necrosis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000003637 Tufted angioma Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 208000009887 angiolipoma Diseases 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003481 parotid region Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 201000009483 spindle cell hemangioma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Abstract
The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for s example of infantile hemangiomas, The beta blocker may be a non selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Description
1 USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS The present application is a divisional application from Australian Patent Application No. 2008313405, the entire disclosure of which is incorporated into the present specification by this cross-reference. 5 Technical field The present invention relates the use of a beta-blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. 10 Also disclosed is a method for the treatment of hemangiomas by using the present invention. In the following text, the bracketed bolded references are references attached to the cited documents and publication also listed in the reference lisiting after the Example part of the specification. 15 Prior art Infantile capillary hemangiomas (IH) Hemangiomas in children are most commonly recognized in the skin and liver. IH Infantile capillary hemanglomas (IH) are the most common soft tissue tumours of infancy, 20 occurring in 4 to 10% of children under 1 year of age as disclosed in Frieden IJ et al, "Infantile hemangiomas: current knowledge, future directions, Proceedings of a research workshop on infantile hemangiomas", Pediatr Dermatol 2005; 22:383-406 [1]. IH is made of a complex mixture of cell types including a 25 majority of endothelial cells, associated with pericytes, dendritic cells and mast cells. Endothelial cells derived from proliferating hemangiomas are clonal in origin as disclosed in document [1] and by Bielenberg D.R. et al, "Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and 30 inversely correlated with expression of the endogenous angiogenesis inhibitor", INF-beta. Int. J. Oncot; 14:401-408 [10], Boye E, et al Clonality and altered behaviour of endothelial cells from hemangiomas. J 2 Clin Invest 2001;107:745-52 [9] suggesting that hemangiomas arise from the clonal expansion of an endothelial precursor cell, which might be derived of a haematopoietic stem cell as disclosed in [1]. IH endothelial cells exhibit a distinctive molecular phenotype s characterized by immuno-histochemical positivity in document [1]: indoleamine 2,3-dioxygenase (IDO) and LYVE-1 both positive in early phase IH and lost during maturation to a blood vascular phenotype, Glucose transporter 1 (Glut-1), Lewis Y Ag (Le Y), FcRyll, merosin, CCR6, and CD 15. 10 Regulators of IH growth and involution are still poor understood, but it has been demonstrated that during their growth phase, two major pro-angiogenic factors are involved: basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) which are present in situ, but also in blood and urines as disclosed in document [1]. 15 and in Mancini AJ. et al, "Proliferation and apoptosis within juvenile capillary hemangiomas", A.m. J. Dermatopathol. 1996; 18:505-514 [113. In addition, in situ hybridization for the VEGF receptor (VEGF R) in proliferative IH has shown that VEGF-Rs are evenly spread throughout the hemangioma and not yet assembled into blood vessels. 20 During the growth phase of IH, histological studies have showed that both endothelial and interstitial cells are in proliferative state (MIB1 staining strongly positive) as disclosed in Mancini et al. Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol 1996;18:505-14 [10] . and on the other hand during the 25 involution phase the cells exhibit markers of apoptosis as disclosed in [10] and Razon MJ. et al, "Increased apoptosis coincides with onset of involution in infantile hemangioma", Microcirculation 1998; 5:189-195 [11] One hypothesis to explain endothelial cell apoptosis in capillary hemangiomas is the expression of ICAM-1 on the cell surface, but an 30 alternative possibility may be the loss of stimulatory factors such as VEGF [1]. The adrenergic system is the major regulator of cardiac and vascular function. Capillary endothelial cells express beta 2-adrenergic 3 receptors as disclosed in D'Angelo G. et al, "cAMP-dependant protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation", J. Cell Biochem. 1997; 67:353-366 [13] which modulate the s release of NO, causing endothelium-dependent vasodilatation. In addition, beta-adrenergic receptors belong to the family of G-protein coupled receptors and when they are activated by adrenergic catecholamines they can promote a series of intracellular signal transduction pathways as disclosed in laccarino G, et al. Ischemic 10 neoangiogenesis enhanced by beta2-adrenergic receptors overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005; 97:1182-1189 [12] and [13]. Beta receptor stimulation can induce modifications of signal transduction pathways of angiogenic factors such as VEGF or bFGF as disclosed in [13]. It has been 15 demonstrated that the increase of cAMP levels inhibit VEGF-and bFGF induced endothelial cell proliferation. Pharmacological or beta-adrenergic receptor-mediated elevations in cAMP block mitogen-induced activation of the MAPK signaling pathway leading to blockade of Raf-1 activity via increased PKA activity [13]. 20 In addition, it has been demonstrated that betablockade can induce apoptosis of cultured capillary endothelial cells as disclosed in Sommers Smith S.K. et al, "Beta blockade induces apoptosis in cultured capillary endothelial cells", In Vitro Cell Dev. Biol. Anim. 2002; 38:298 304 [14]. 25 Despite their benign self-limited course, common IH are rarely responsible during their proliferative phase for local complications such as ulceration or haemorrhage. The so-called alarming HI disclosed for example in Enjolras 0. et al. "Management of alarming hemangiomas in 30 infancy: a review of 25 cases", Pediatrics 1990;85:491-8 [4] can impair vital or sensorial functions especially when present respectively on upper airways and orbital areas.
4 In addition, IH cause at least transient cosmetic disfigurement which trigger psychological morbidity first in parents and later in affected children as disclosed in document [1] and in Tanner J.L. et al, "Growing up with a facial hemangioma: parent and child coping and adaptation, s Pediatrics", 1998; 101:446-452 [2]. Systemic or intralesional corticosteroids are used as first line treatments for problematic lesions during the proliferative phase as disclosed in Bennett ML et al, Oral corticosteroid use is effective for cutaneous hemangiomas, An evidence-based evaluation, Arch. 10 Dermatol. 2001; 137 :1208-13 [3]. However, even at high dosages (2 to 5mg/kg of body weight/day), response rates to treatment range from 30 to 60% as disclosed in documents [1], [3] and [4]. Adverse effects are usually transient and limited such as cushingoid facies, irritability, growth 15 suppression, but may cause more concern hypertrophic myocardiopathy. Other treatment options include interferon alfa-2a and 2b (40 to 50% of complete response with dosing 1-3 mU/m 2 /day) (millions of units per m2 ) but a risk of neurotoxicity has been reported in children under 1 year of age, as disclosed in documents [1] and [5]; vincristine is 20 also used for its antimitotic properties as disclosed in document [1] but its well-known downsides are peripheral neuropathy, constipation, and hematologic toxicity. Further, the new anti-angiogenic factors such as avastatin are contra-indicated in young children because of their side effects. 25 Moreover, because most patient receiving treatment are infant or small children, patient tolerance for the known compounds becomes of more paramount importance. Thus, needs exist of alternative, more efficient and less toxic 30 compounds for the treatment of IH, in particular of infantile capillary haemangiomas. The present invention fulfills these and other needs.
5 Description of the invention Propranolol is a well tolerated non-selective beta blocker commonly used in young children for cardiologic indications as disclosed by Villain E et al in Low incidence of cardiac events with beta-blocking 5 therapy in children with long QT syndrome, Eur. Heart J. 2004; 25:1405 11 [6], by Fritz KI. et al, Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive card omyopathy in premature infants: three case reports and literature review. J Perinatol 1998;18:38-44 [7], and by Kilian K. in Hypertension in neonates causes 10 and treatments, J. Perinat Neonatal Nurs. 2003; 17:65-74 [8]. But this beta-blocker and beta-blockers in general have never been experimented nor disclosed for a use in the treatment of haemangiomas. The present inventors are the first ones to have experimented and observed that beta-blockers may be very efficient to control the 15 growth of IH and even to treat IH. The observations and experimental results are provided in the present application. Accordingly, in a first aspect, the present invention provides the use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas. 20 < Beta blocker refers also herein to beta-receptor blocking agent, beta adrenergic receptor blocking agent, beta blocking agent, beta-blocking agent or beta-adrenergic receptor blocking agent or any other denomination indicating a chemical that inhibits the binding of agonists, natural or artificial, to beta-adrenergic receptors of any type 25 (beta-1, beta-2, beta-3 or others). According to the present invention, the beta blocker may be a non-selective beta blocker, a beta-I -selective beta blocker, a mixture of alpha-1/beta-adrenergic antagonists, a beta-2-selective beta blocker. The beta-blocker may also be a mixture of two or more beta-blockers. 30 Examples of beta blocker that may be used in the present invention are disclosed in Goodman and Gilman's the pharmacological basis of therapeutics, eleventh edition, chapter 10, pp 271-295, 2006 [19].
6 Preferably, according to the present invention, when a non selective beta blocker is used, it may be selected for example from the group comprising alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, s penbutolol, pindolol, propafenone (propafenone is a sodium channel blocking drug that also is a beta-adrenergic receptor antagonist), propranolol, sotalol, timolol or pharmaceutically acceptable salts therof, A mixture thereof may be used. When a beta-1 selective beta blocker is used according to the 10 present invention, it may be selected for example from the group comprising acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol, nebivolol. The beta blocker may also have an intrinsic sympathomimetic activity as acebutolol, betaxolol, carteolol, carvedilol, labetalol, oxprenolol, is penbutolol, pindolol, propranolol Preferably, the beta blocker is propranolol or a pharmaceutically salt thereof, for example L or D-propranolol or a mixture thereof. The mixture may be a mixture of L and D-propranolol, with an amount thereof of 0:1 to 1:0, for example 1:1. Pharmaceutically acceptable salt of the 20 propranolol may be propranolol hydrochloride or any other preparation of propranolol, whether or not the preparation changes or alters the pharmacokinetic properties or metabolisation of propranolol. According to the present invention, the medicament may be a medicament for treating infantile capillary hemangiomas. 25 According to the present invention, the medicament may also be a medicament for treating other vascular tumors, for example those selected from the group comprising hemangiomas (i.e. epitheliod hemangioma, sinusoidal hemangioma, spindle cell hemangioma), tufted angioma, hemangioendotheliomas (i.e, kaposiform 30 hemangioendothelioma), hemangioma in the von Hippel-Lindau syndrome, angiofibroma and angiolipoma in Boumeville disease, pyogenic granuloma, angiosarcomas, for example Kaposi's sarcoma, expanding arteriovenous malformations, tumor-associated vascular 7 proliferation. Reference M, Wassef and coil. Vascular tumours and malformations, classification, pathology and imaging. Ann Chir Plast Esth 2006; 51:263-281 [20] discloses anatomopathologic classification of these active proliferation tumors. 5 The medicament may be in any form that can be administred to a human or an animal. Administration may be carried out directly, i.e. pure or substantially pure, or after mixing of the beta-blocker with a pharmaceutically acceptable carrier and/or medium. According to the present invention, the medicament may be a 10 syrup or an injectable solution. According to the present invention, the medicament may be a medicament for oral administration selected from the group comprising a liquid formulation, an oral effervescent dosage form, an oral powder, a multiparticule system, an orodispersible dosage form. is For example, when the medicament is a medicament for oral administrartion, it may be in the form of a liquid formulation selected from the group comprising a solution, a syrup, a suspension, an emulsion and oral drops. When the medicament is in the form of an oral effervescent dosage form, it may be in a form selected from the group comprising 20 tablets, granules, powders. When the medicament is the form of an oral powder or a multiparticulate system, it may be in a form selected from the group comprising beads, granules, mini tablets and micro granules. When the medicament is the form of an orodispersible dosage form, it may be in a form selected from the group comprising orodispersible tablets, 25 lyophilised wafers, thin films, a chewable tablet, a tablet and a capsule, a medical chewing gum. According to the present invention, the medicament may be a medicament for buccal and sublungual routes, for example selected from the group comprising buccal or sublingual tablets, muco adhesive 30 preparation, lozenges, oro-mucosal drops and sprays. According to the present invention, the medicament may be a medicament for topical-transdermal administration, for example selected from the group comprising ointments, cream, gel, lotion, patch and foam.
8 According to the present invention, the medicament may be a medicament for nasal administration, for example selected from the group comprising nasal drops, nasal spray, nasal powder. According to the present invention, the medicament may be a 5 medicament for rectal administration, for example suppository or hard gelatin capsule. According to the present invention, the medicament may be a medicament for parenteral administration, for example subcutaneous, intramuscular, intravenous adminsitration. 10 The skilled person in the art understands clearly that the term "form" as used herein refers to the pharmaceutical formulation of the medicament for its practical use. For example, the medicament may be in a form selected from the group comprising an injectable form (for example as Avlocardyl®5mg/ml), syrup (for example as Efferalgant3%), oral is suspension (for example as Efferalgan*3% ), a pellet (for example as Dafalgan 1g), powder (for example as Doliprane '100mg ), granules (for example as Zoltum"10mg ), spray, transdermal patch (for example as Cordipatch5mg/24h ) or local form (cream, lotion, collyrium) (for example as Dermoval creme, as Betnevalflotion and as Chibroxine> collyre 20 respectively). In these examples, the beta blocker, for example on of the above-cited beta blockers, for example propranolol, may be added or may replace the active ingredient(s) of said medicaments. The pharmaceutical acceptable carrier may be any know 25 pharmaceutically carrier used for the administration of a beta-blocker to a human or to an animal, depending on the subject. For example, this carrier may be selected from the group comprising for example the monomdthoxy-poly6thy6neglycol (for exemple as in Viraferonpeg") or Liposome (for exemple as in Ambizome"). 30 The medium may be any know medium used for the administration of a beta-blocker to a human or to an animal. For example, this medium may be selected from the group comprising for example 9 cremophor (for exemple as in Sandimmun") or cellulosis (for exemple as in Avlocardy > LP160mg). The pharmaceutical form of the drug is selected with regard to the human or animal to be treated. For example, for a child or a baby, a S syrup or an injection is preferred. Administration may be carried out with a weight graduated pipette. According to the present invention, the medicament may comprise any pharmaceutically acceptable and efficient dose of the beta blocker to treat hemangiomas. For example, the medicament may 10 comprise a dose allowing an administration of 1 to 5 mg/kg of body weight per day, for example of 2 to 4 mg/kg of body weight/day. In a second aspect, the present invention provides a method of treating a subject suffering from hemangiomas is also disclosed. This method comprises the step of administering to said subject a beta-blocker. 15 Hemangiomas and beta-blockers, as well as usable formulations are as defined above. The administration can be made by using any pharmaceutical way known by the skilled person and useful to administrate a beta-blocker. Examples of administrable forms of medicament are provided above. For 20 example, the administration can be made by direct injection of the beta blocker. This way of administration, as well as a syrup, is of course preferred for babies. The administration may be defined so as to allow delivery of a pharmaceutically acceptable and efficient dose for the treatment of 25 hemangiomas. For example, the administration may comprise a dose of 1 to 5 mg/kg of body weight per day, for example of 2 to 4 mg/kg of body weight/day.The administration may be carried out with one dose or with a plurality of doses per day. 30 The inventors of the present application demonstrate clearly experimentally a strong anti-angiogenic effect in infantile capillary hemangiomas (IH) by the use of a beta-blocker.
10 Further searches carried out by the present inventors with regard to hemangioma show that adrenergic beta2 receptors are present at the surface of the endothelial cells of hemangioma (see examples below). This confirms the results obtained with the present invention, 5 provides physiopathological explanations and confirms the mechanism of action of beta-blockers in the frame of the present invention. This confirms also the link between efficiency of propranolol and its activity as beta blocker. Since the new anti-angiogenic factors of the prior art such as 10 avastatin are contra-indicated in young children because of their side effect, the use of propranolol according to the present invention constitutes a safe alternative to systemic corticosteroids, and even to interferon or vincristine. Propranolol is a non-selective beta-blocker with weak intrinsic 15 sympathomimetic activity, and its dramatic therapeutic effect on IH could be explained by three mechanisms: 1. a peripheral vasoconstrictor effect inducing cell hypoxia, Propranolol is responsible for peripheral vasoconstriction, and this effect is immediately visible on the IH we have 20 treated. 2. a decreased expression of VEGF and bFGF genes via the down regulation of the Raf/MAPK pathway, or the HIF pathway (Giatromanoloki A, Arvanitidou V, Hatzimichael A, Simopoulos C, Sivridis E [17]. The HIF-2alphaNEGF 25 pathway activation in cutaneous capillary haemangiomas (Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Cardiovedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded 30 rat heart. J Biomed Sci. 2005 ; 12 : 409-420[181), 3. an apoptosis triggering effect on capillary endothelial cells.
11 In the experimental results disclosed hereunder, a change in color from intense red to purple, associated with a palpable softening of the lesion was observed on babies presented with an IH. This effect could induce a chronic hypoxia of the hemangioma responsible for an arrest of 5 endothelial cell prolferation. However, in inventor's experimentations, the progressive improvement of IH under propranolol treatment suggests strongly a sustained action on proliferative growth factors. It is not clear whether in this respect the targets of the treatment 10 are the endothelial cells themselves, or other cells such as interstitial cells or mast cells. The third mechanism possibly involved to explain the involution of IH is an early endothelial cell apoptosis induced by the beta blockade. However the re-growth of the hemangioma in two of the 15 presented cases, when the treatment was stopped during the proliferative phase of the IH, does not support this hypothesis. In addition, in the second case the inventors did not find apoptotic cell markers by immuno histochemistry using antibodies to cleaved caspases 3 and 8. Further, the use of beta-blockers is now widespread in neonate 20 or children patients with a good tolerance in cardiac diseases as long QT syndrome as shown in document Villain E. et al, "Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome', Eur. Heart J. 2004; 25:1405-1411 [6], hypertrophic cardiomyopathie as shown in document Fritz K.I. et al, "Effect of beta-blockade on symptomatic 25 dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review", J. Perinatal 1998; 18:38-44 [7J or hypertension as shown in document Kilian K. et al, "Hypertension in neonates causes and treatments", J. Perinat. Neonatal Nurs 2003; 17: 65-74 [8]. 30 This invention is further illustrated by the following examples with regard to the annexed drawings that should not be construed as limiting.
12 Brief description of the drawings - Figure 1 is a picture showing the aspect of a hemangioma after 4 weeks of a prior systemic steroids treatment, before beginning of 5 propranolol treatment. - Figure 2 is a picture showing the aspect of the hemangioma only seven days after onset of propranolol treatment according to the present invention. - Figure 3 is a picture showing experimental results at 6 months of age 10 where the child still continues to be treated according to the present invention and prior systemic steroids treatment was stopped since 2 months. - Figure 4 is a picture showing the experimental results at 9 months of propranolol treatment according to the present invention. 15 - Figures 5 is a picture obtained with a method of immunohistochemistry showing that beta2 receptors are expressed on endothelial cells of IH - Figures 6 is a picture obtained with a method of immunohistochemistry showing that HIF1 alpha (red staining) are expressed on endothelial cells of IH. 20 EXAMPLES Example 1 : first experiments according to the present invention A male baby presented with an IH involving the nasal pyramid. 25 At 2 months of age, systemic steroids were introduced because of dyspnea associated with nasal partition and columella necrosis. After a one-month treatment at 3 mg/kg of body weight/day (mg/kg/day] of prednisolone, the hemangioma was stabilized, but nasal necrosis progressed. Since the infant progressively refused to take prednisolone 30 tablets, we introduced an equivalent dosage of bethamethasone in drops (0,5mg/kg/day). At 4 months of age, the hemangioma had stopped growing and intra nasal ulcerations had healed.
13 However, the child returned at a control visit with tachycardia at 180 to 200 pulses per minute, associated with a systolic cardiac murmur. A cardiac sonography showed an obstructive hypertrophic myocardiopathy, justifying a decrease of the betamethasone dosage from 5 3 to 2 mg/kg of body weigth /day (mg/kg/day). We have thus initiated a treatment with a beta-blocker, propranolol (chemical IUPAC name: (2RS)-1-[1-methylethyl)aminoj 3(naphtalen-1 yloxy)propan-2-ol) at 3 mg/kg/day. Propranolol was administred as a capsule containing commercial propranolol powder. The 10 day after the onset of propranolol treatment the hemangioma changed in color from intense red to purple, and softened. Betamethasone was replaced by prednisolone which was progressively tapered down and stopped 6 weeks after initiation of propranolol. Despite the decrease of systemic steroids, the IH still continued i5 to improve. At age 5 months Y2, when steroids had been stopped, no rebound in size or coloration of the IH could be noted. At 14 months of age, the child was still under propranolol, and the corticosteroid-induced hypertrophic cardiomyopathy had regressed. The IH was completely flat, with the persistence of only skin telangiectasias on a yellow-orange 20 dyscolored skin background, and sequels of intranasal and columella necrosis. Example 2: second experiment according to the present invention The second infant, a male triplet, born at 30 weeks, presented 25 since birth a plaque-like IH involving the entire right upper limb and the right fronto-parietal and superior eyelid areas. At one month of age a subcutaneous component developed in 3 areas including the superior eyelid, the parotid region and the axillary fold. Because of risk of visual deprivation prednisolone was started at 3 30 mg/kg/day. However, after 2 weeks of treatment the situation was not under control and we decided to increase prednisolone at 5 mg/kg/day for 2 weeks.
14 Despite this regimen the IH continued to enlarge and at 2 months of age eyelid opening was impossible, the right side of the face being deformed by an enormous tumor as shown in annexed figure 1. In addition the axillary fold was occupied by a tumoral IH component s measuring clinically 5 cm in diameter. MRI showed no intra-cerebral anomalies, but revealed that the IlH involved extra and intraconal orbital areas and was responsible for exophthalmia. In addition, MRI showed that the parodital IH was in continuity with a compressive intra-cervical component leading to tracheal 10 and oesophageal deviation; the axillary mass measured 26mm x 45mm x 40mm and extended to the right pulmonary apex. A cardiac sonography showed an increased cardiac output. The dosage of prednisolone was reduced to 3 mg/kg/day and a treatment with Propranolol, 2 mg/kg/day, according to the present 15 invention, was initiated. Like in the previous infant (see above example 1), the lesions softened only 12 hours after the onset of propranolol. Seven days after, spontaneous ocular opening was possible due to a dramatic reduction in size of the subcutaneous component of the 20 hemangioma as shown in the picture presented in annexed figure 2. Parotidal and axillary masses were considerably reduced in size. These unexpected results obtained with the present invention have to be compared with those presented in the picture of annexed figure I that shows the aspect of the hemangioma before onset of propranolol 25 treatment and after 4 weeks of a prior art systemic steroids treatment (2 weeks at 3 mg/kg/d and 2 weeks at 5 mg/kg/d). Prednisolone treatment was progressively tapered down while the IH continued to improve. At 3 months of age a biopsy sample was obtained on the arm, showing a typical IH. Endothelial cells demonstrated 30 poor staining with the monoclonal antibody MIB-1 suggesting a weak proliferative activity for an IH in a young infant. In order to assess a possible proapoptotic role of propranolol, immuno-histochemical analysis using monoclonal anti-cleaved caspase-3 15 and 8 antibodies (Ozyme, Saint Quentin en Yvelines, France), was performed but did not demonstrate positive immunostaining [15]. Prednisolone was stopped at 4 months of age, without any rebound, but a 3-day interruption of propranolol treatment was responsible s for a mild increase in size of the hemangioma on the superior eyelid and parotidal areas. Reintroduction of propranolol treatment at 2mg/kg/day was successful after only 24 hours. At 6 months of age, the eye opening was satisfactory and no 10 major visual impairment was noted, the parotidal and axillary subcutaneous hemangiomatous components were not palpable and the IH had considerably faded on both face and arm. Figure 3 provides a picture showing these experimental results at 6 months of age where the child still continue to take 2 mg/kg/d of 15 propranolol but systemic steroids were stopped since 2 months. No subcutaneous component of the hemangioma was noted, and the cutaneous component had considerably faded. In addition the child does not suffered of any visual impairment. At 9 months of age, the treatment was stopped, without any re 20 growth of the IH as shown in the picture of annexed figure 4. Example 3: third experimentation according to the present invention A baby girl presented with a right periocular IH noted first at 3 weeks of age and localized on the internal canthus. At 2 months of age, 25 the subcutaneous component of the IH extended into the orbit and limited the opening of the superior eyelid. Doppler ultrasonography showed an IH measuring 32mm in diameter and 12mm in thickness. After informed consent obtained from the parents, she was 30 treated with propranolol 2 mg/kg/day. Flattening of the lesion was noted in 12 hours, followed by a progressive improvement.
16 Control ultrasonography, performed 7 days after the onset of propranolol, showed a decrease in size of the IH: 21mm in diameter versus 32mm and 6mm in thickness versus 12mm, without any hemodynamic modifications. 5 Propranolol was stopped after one month, but a novel increase in size of the IH was noted, necessitating the treatment to be resumed. At 7 months of age the IH was flat and had faded in color, and ultrasonography could not identify any subcutaneous component. Propranolol was stopped at 8 months without any rebound of 10 the hemangioma. Seven other child suffering from hemangiomas have been treated with propranolol and similar results were obtained. No treatment failure has been observed with the present invention. This kind of results 15 were never achieved in the prior art, for example with corticotherapy or interferon. In summary, these examples show clearly that propranolol has a strong anti-angiogenic effect in IH. Since the new anti-angiogenic factors such as avastatin are contra-indicated in young children because of their 20 side effects, propranolol, may constitute a reasonable safe alternative to systemic corticosteroids, and even to interferon or vincristine. Example 4: Comments and further experimental results The inventors have serendipitously observed that propranolol, 25 well tolerated non-selective beta-blocker commonly used in young children for cardiologic indications, can control the growth phase of IH as reported in L6aut6-Labr6ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB. Propranolol for severe hemangiomas of infancy. New Engl J Med 2008, 358; 24:2650-51 [16]. A possible explanation of the skewed 30 sex ratio, and that the activation of the HIF-2alpha pathway and the subsequent overexpression of VEGF by endothelial cells are involved in the pathogenesis of cutaneous capillary haemangiomas 17 (Giatromanolaki et al, The HIF-2alphaNEGF pathway activation in cutaneous capillary haemangiomas. Pathology 2005:149-51 [17]). Surprisingly, studing betablockers for the treatment of cardiac hypertrophia, Shyu et al. revealed that cardivedilol reverses both protein 5 and mRNA of HIF-lalpha and VEGF to the baseline values (Shyu et al., Cardiovedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-lalpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005 ; 12 :409-420 [18]). Further searches are conduced looking at the angiogenic cascade 10 downstream of beta adrenergic receptors in vivo and in vitro in IH and at possible genetic determinants influencing the HI phenotype. Histology and immunohistochemistry Skin biopsy were embedded in paraffin, cut into 5pm sections is and stained with hematoxylin-eosin to assess the general morphology. To visualize the presence of alpha2-adrenergic receptor and the level of expression of HIFI-alpha, sections were incubated respectively with monoclonal rabbit anti-human alpha2-adrenergic receptor 1:100 (PA1 20659, ABR, Golden, USA) or monoclonal mouse anti-human HIF1 20 alphal1:1000 (ab8366, abcam, Cambridge, UK) overnight at 4"C. As secondary system, we used Envision horseradish peroxidase system (K4002, K4000 Dako, Trappes, France) which enhances staining sensitivity directed against rabbit for alpha2-adrenergic receptor and mouse for HIF1-alpha Sections were revealed with 25 aminoethylcarbamide (K3461, Dako, Trappes, France) and counterstained with hematoxylin. Preliminary immunohistochemistry findings showed that beta2 receptors (annexed figure 5) are expressed on endothelial cells of IH. HIFI alpha ( annexed figure 6) was also expressed on endothelial cells of 30 IH as recently observed.
18 Reference listing [1] Frieden IJ, Haggstrom A, Drolet BA, Mancini AJ, Friedlander SF, 5 Boon L, and coll. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol 2005; 22:383-406. [2] Tanner JL, Dechert MP, BA; Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics. 1998; 101:446-452. [3] Bennett ML, Fleischer AB, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas. An evidence-based evaluation. Arch Dermatol 2001 ; 137 :1208-13. [4] Enjolras 0, Riche MC, Merland JJ, Escande JP Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990;85:491-8. [5] Ezekowitz RAB, Phil CBD, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New Engl J Med 1992; 326:1456-63. [6] Villain E, Denjoy 1, Lupoglazoff JM, Guicheney P, Hainque B, Lucet V, Bonnet D. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 2004; 25:1405-11. [7] Fritz KI, Bhat AM. Effect of beta-blockade on symptomatic 2E Sdexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. J Perinatol 1998; 18:38-44. [8] Kilian K. Hypertension in neonates causes and treatments. J Perinat Neonatal Nurs 2003; 17:65-74. 30 [9] Boye E, Yu Y, Paranya G, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behaviour of endothelial cells from hemangiomas. J Clin Invest 2001;107:745-52.
19 [10] Mancini AJ, Smoller BR. Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol 1996;18:505-14. [11] Razon MJ, Kraling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution in infantile hemangioma. 5 Microcirculation 1998; 5:189-95. [12] laccarino G, Ciccarelli M, Soriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante 0, Pastore L, Chiarello M, Salvatore F, Koch WJ, Trimarco B. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptors overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005; 97:1182-1189. [131 D'Angelo G, Lee H, Weiner RI. cAMP-dependant protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67:353-366. [14] Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298-304. [15] Chaturvedi V, Sitailo LA, Bodner B, Denning MF, Nickoloff BJ. 20 Defining the caspase-containing apoptotic machinery contributing to cornification in human epidermal equivalents.Exp Dermatol. 2006 Jan;15(1):14-22. [16] L6aut6-Labr6ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB. Propranolol for severe hemangiomas of infancy. New 25, Engl J Med 2008, 358; 24:2650-51. [17] Giatromanoloki A, Arvanitidou V, Hatzimichael A, Simopoulos C, Sivridis E. The HIF-2alpha/VEGF pathway activation in cutaneous capillary haemangiomas. Pathology 2005:149-51. [18] Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Cardiovedilo prevents cardiac hypertrophy and overexpression of hypoxia inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005 ; 12 :409-420.
20 [19] Goodman and Gilman's the pharmacological basis of therapeutics, eleventh edition, chapter 10, pp 271-295, 2006. [20] M. Wassef and coil. Vascular tumours and malformations, classification, pathology and imaging. Ann Chir Plast Esth 2006; 5 51:263-281. There is disclosed: 1. Use of a beta blocker for the manufacture of a 10 medicament for the treatment of hemangiomas. 2. The use according to item 1 above, wherein the beta blocker is selected from the group comprising a non-selective beta blocker, a beta-1-selective beta blocker, a mixture of alpha-1/beta is adrenergic antagonists, a beta-2-selective beta blocker and a mixture of two or more beta-blockers. 3. The use according to item 1 above, wherein the beta blocker is a non-selective beta blocker. 20 4. The use according to item 3 above, wherein the non selective beta blocker is selected from the group comprising alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, 25 propafenone, propranolol, sotalol, timolol, pharmaceutically acceptable salts therof and mixture thereof. 5. The use according to item 1 or 2 above, wherein the beta blocker is a beta-1 selective beta blocker. 30 21 6. The use according to item 5 above, wherein the beta-1 selective beta blocker is selected for example from the group comprising acebutolol, atenoloi, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol, nebivolol. 5 7. The use according to item 1 above, wherein the beta blocker has an intrinsic sympathomimetic activity. 8. The use according to item 7 above, wherein the beta 10 blocker is selected from the group comprising acebutolol, betaxolol, carteolol, carvedilol, labetalol, oxprenolol, penbutolol, pindolol, propranolol. 9. The use according to item 1 above, wherein said beta blocker is propranolol or a pharmaceutical salt thereof. 15 10. The use according to any one of items 1-9 above, wherein the medicament is a medicament for treating capillary hemangiomas and/or capillary infantile hemangiomas. 20 11. The use of any of items 1-10 above, wherein the medicament is a syrup or an injectable solution. 12. The use of any of items 1-10 above, wherein the medicament is a medicament for oral administration selected from the 25 group comprising a liquid formulation, an oral effervescent dosage form, an oral powder, a multiparticule system, an orodispersible dosage form. 13. The use according to item 12 above, wherein the medicament for oral administration is a liquid formulation selected from the 30 group comprising a solution, a syrup, a suspension, an emulsion and oral drops.
22 14. The use of any of items 1-10 above, wherein the medicament is a medicament for buccal and sublungual routes. 15. The use of any of items 1-10 above, wherein the 5 medicament is a medicament for topical-transdermal administration. 16. The use according to item 15 above, wherein the medicament for topical administration is selected from the group comprising ointments, cream, gel, lotion, patch, foam. 10 17. The use of any of items 1-10 above, wherein the medicament is a medicament for nasal administration. 18. The use of any of items 1-10 above, wherein the 15 medicament is a medicament for rectal administration. 19. The use of any of items 1-10 above, wherein the medicament is a medicament for parenteral administration. 20 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or 25 addition of further features in various embodiments of the invention. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, 30 in Australia or any other country.
Claims (20)
1. Use of propranolol hydrochloride for the manufacture of a medicament for the treatment of hemangiomas. 5
2. The use according to claim 1, wherein the propranolol is L- or D- propranolol.
3. The use according to claim 1 or 2, wherein the 10 medicament is a medicament for treating capillary hemangiomas and/or capillary infantile hemangiomas.
4. The use of any one of claims 1-3, wherein the medicament is a syrup or an injectable solution. 15
5. The use of any one of claims 1-3, wherein the medicament is a medicament for oral administration selected from the group consisting of a liquid formulation, an oral effervescent dosage form, an oral powder, a multiparticule system and an orodispersible dosage form. 20
6. The use of any one of claims 1-3, wherein the medicament for oral administration is a liquid formulation selected from the group consisting of a solution, a syrup, a suspension, an emulsion and oral drops. 25
7. The use of any one of claims 1-3, wherein the medicament is a medicament for buccal and sublingual routes.
8. The use of any one of claims 1-3, wherein the medicament 30 is a medicament for topical-transdermal administration. 24
9. The use according to claim 8, wherein the medicament for lopical-transdermal administration is selected from the group consisting of an ointment, cream, gel, lotion, patch and foam. 5
10. The use of any one of claims 1-3, wherein the medicament is a medicament for nasal administration.
11. The use of any one of claims 1-3, wherein the medicament is a medicament for rectal administration. 10
12. The use of any one of claims 1-3, wherein the medicament is a medicament for parenteral administration.
13, A method for the treatment of hemangiomas comprising is administration of propranolol hydrochloride to a subject in need thereof.
14. The method according to claim 13, wherein the propranolol is L- or D- propranolol. 20
15. The method according to claim 13 or 14, wherein the medicament is a medicament for treating capillary hemangiomas and/or capillary infantile hemangiomas.
16. The method of any one of claims 13-15, wherein the 25 medicament is a syrup or an injectable solution.
17. The method of any one of claims 13-15, wherein the medicament is a medicament for oral administration selected from the group consisting of a liquid formulation, an oral effervescent dosage form, 30 an oral powder, a multiparticule system and an orodispersible dosage form. 25
18. The method of any one of claims 13-15, wherein the medicament for oral administration is a liquid formulation selected from the group consisting of a solution, a syrup, a suspension, an emulsion and oral drops. 5
19. The method of any one of claims 13-15, wherein the medicament is a medicament for buccal and sublungual routes.
20. The method of any of claims 13-15, wherein the 10 medicament is a medicament for topical-transdermal administration, selected from the group consisting of an ointment, cream, gel, lotion, patch and foam.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014201660A AU2014201660B2 (en) | 2007-10-19 | 2014-03-19 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291273.6 | 2007-10-19 | ||
US60/989,507 | 2007-11-21 | ||
AU2008313405A AU2008313405B2 (en) | 2007-10-19 | 2008-10-16 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
AU2014201660A AU2014201660B2 (en) | 2007-10-19 | 2014-03-19 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008313405A Division AU2008313405B2 (en) | 2007-10-19 | 2008-10-16 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2014201660A1 AU2014201660A1 (en) | 2014-04-10 |
AU2014201660B2 true AU2014201660B2 (en) | 2015-09-03 |
Family
ID=50439641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014201660A Active AU2014201660B2 (en) | 2007-10-19 | 2014-03-19 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2014201660B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040830A1 (en) * | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Therapeutic treatment for vegf related diseases |
-
2014
- 2014-03-19 AU AU2014201660A patent/AU2014201660B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040830A1 (en) * | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Therapeutic treatment for vegf related diseases |
Non-Patent Citations (6)
Title |
---|
BREM, H. et al. "The Combination of Antiangiogenic Agents to Inhibit Primary Tumor Growth and Metastasis" Journal of Pediatric Surgery (1993) Vol.28 No.10 pages 1253 to 1257 * |
LUTGENDORF, S.K. et al. "Stress-Related Mediators Stimulate Vascular Endothelial Growth Factor Secretion by Two Ovarian Cancer Cell Lines" Clinical Cancer Research (2003) Vol.9 No.12 pages 4514 to 4521 * |
RAZON, M.J. et al. "Increased Apoptosis Coincides with Onset of Involution in Infantile Hemangioma" Microcirculation (1998) Vol.5 No.2-3 pages 189 to 195 * |
SOMMERS SMITH, S.K. et al. "Beta blockade induces apoptosis in cultured capillary endothelial cells" In Vitro Cellular and Developmental Biology Animal (2002) Vol.38 No.5 pages 298 to 304 * |
SOZZANI, S. et al. "Propanol, a Phosphatidate Phosphohydrolase Inhibitor, Also Inhibits Protein Kinase C" Journal of Biological Chemistry (1992) Vol.267 No.28 pages 20481 to 20488 * |
THAKER, P.H. et al. "Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma" Nature Medicine (2006) Vol.12 No.8 pages 939 to 944 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014201660A1 (en) | 2014-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008313405B2 (en) | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | |
US8987262B2 (en) | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | |
Young et al. | Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis | |
US10617735B2 (en) | Methods and compositions for preserving retinal ganglion cells | |
RU2426532C2 (en) | Application of organic compounds | |
AU2018241165A1 (en) | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | |
JP7242097B2 (en) | Anticancer composition containing immune checkpoint inhibitor | |
US20210000810A1 (en) | Pharmaceutical combination comprising lsz102 and alpelisib | |
US20040001818A1 (en) | Methods of inhibiting angiogenesis using NADPH oxidase inhibitors | |
US20060035825A1 (en) | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | |
AU2014201660B2 (en) | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | |
JP2018109055A (en) | Compositions and methods for the treatment of retinal degeneration | |
SA08290744B1 (en) | Use of a Beta Blocker for the Manufacture of a Medicament for the Treatment of Hemangiomas | |
US11351229B2 (en) | Combination therapies for treating infantile spasms and other treatment resistant epilepsies | |
US20130095059A1 (en) | Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model | |
WO2023086363A2 (en) | Methods of treating glioblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |